Citigroup reaffirmed a 'buy' rating on shares of Fortress Biotech.
2 reports, 1 independent
Updated Aug 15
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Citigroup reaffirmed a 'buy' rating on shares of Fortress Biotech.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Citigroup
American investment bank and financial services corporation
-
Fortress Biotech
company
Nothing else this week.
Related events
- Citigroup restated a buy rating on shares of Intensity Therapeutics.
- Citigroup reiterated a buy rating on Halma shares.
- Citigroup upgraded its target price and gave a buy rating for Fortrea.
- Citigroup reissued a buy rating on Bankinter.
- Citigroup and Jefferies Financial Group raised their price targets and issued buy ratings for Beauty.